Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.
Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.
While the MET pathway is significant in predicting gastrointestinal (GI) cancers, it is a redundant pathway, said Shah. There are many ways to activate the pathways and increase pro-survival signaling, such as through EGFR, HER2 or IGFR, according to Shah.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More